Howard Capital Management Inc. Invests $221,000 in BioNTech SE Sponsored ADR $BNTX

Howard Capital Management Inc. purchased a new position in BioNTech SE Sponsored ADR (NASDAQ:BNTX) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 2,079 shares of the company’s stock, valued at approximately $221,000.

Several other hedge funds have also recently modified their holdings of the business. Mitsubishi UFJ Asset Management Co. Ltd. raised its stake in shares of BioNTech by 9.1% in the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 2,494 shares of the company’s stock worth $227,000 after purchasing an additional 209 shares during the last quarter. SBI Securities Co. Ltd. raised its stake in shares of BioNTech by 7.1% in the first quarter. SBI Securities Co. Ltd. now owns 3,673 shares of the company’s stock worth $334,000 after purchasing an additional 244 shares during the last quarter. LRI Investments LLC raised its stake in shares of BioNTech by 234.6% in the second quarter. LRI Investments LLC now owns 445 shares of the company’s stock worth $47,000 after purchasing an additional 312 shares during the last quarter. Banque Cantonale Vaudoise purchased a new position in shares of BioNTech in the first quarter worth $36,000. Finally, GF Fund Management CO. LTD. raised its stake in shares of BioNTech by 22.0% in the first quarter. GF Fund Management CO. LTD. now owns 2,514 shares of the company’s stock worth $229,000 after purchasing an additional 453 shares during the last quarter. Hedge funds and other institutional investors own 15.52% of the company’s stock.

BioNTech Stock Performance

NASDAQ:BNTX opened at $104.67 on Friday. The stock has a 50-day simple moving average of $102.66 and a two-hundred day simple moving average of $104.87. BioNTech SE Sponsored ADR has a 52-week low of $81.20 and a 52-week high of $129.27. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.48 and a current ratio of 8.61. The firm has a market capitalization of $23.57 billion, a PE ratio of -65.42 and a beta of 1.45.

BioNTech (NASDAQ:BNTX) last released its quarterly earnings results on Monday, August 4th. The company reported ($1.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.41) by ($0.19). BioNTech had a negative net margin of 12.20% and a negative return on equity of 1.84%. The company had revenue of $306.46 million for the quarter, compared to the consensus estimate of $161.26 million. During the same period in the prior year, the firm posted ($3.36) EPS. The business’s revenue for the quarter was up 102.6% on a year-over-year basis. BioNTech has set its FY 2025 guidance at EPS. Analysts forecast that BioNTech SE Sponsored ADR will post -3.88 EPS for the current year.

Analyst Ratings Changes

Several research firms have recently weighed in on BNTX. Morgan Stanley decreased their price target on BioNTech from $133.00 to $131.00 and set an “overweight” rating for the company in a research note on Friday, October 10th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BioNTech in a report on Tuesday, October 14th. Wells Fargo & Company set a $150.00 price objective on BioNTech and gave the stock an “overweight” rating in a report on Tuesday, August 5th. Bank of America cut their price objective on BioNTech from $134.00 to $130.00 and set a “buy” rating for the company in a report on Wednesday, October 22nd. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $136.00 price objective on shares of BioNTech in a report on Monday, September 8th. Ten research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $133.96.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.